MULTIPLE MYELOMA REFRACTORY

This study tests a new treatment called anti-BCMA CAR-T cell therapy for adults with multiple myeloma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The goal is to s…

This study tests a drug called selinexor combined with low-dose dexamethasone, with or without bortezomib, in people with multiple myeloma that has stopped responding to many other treatments. The goal is to see if these combinations can shrink tumors and control the disease. Abo…

This early study tests a new treatment called BCMA-UCART, which uses donor immune cells engineered to find and attack a protein (BCMA) on multiple myeloma cells. It is for adults whose cancer has returned or not responded to at least two prior treatments. The main goals are to ch…

This study tests a new drug called inobrodib combined with two standard medicines (pomalidomide and dexamethasone) in 100 adults whose multiple myeloma has come back or no longer responds to available therapies. The goal is to see how well the combination shrinks or controls the …

This study looks at multiple myeloma patients who are receiving a type of immunotherapy called a BCMA-directed T cell engager. These treatments can weaken the immune system and raise the risk of serious infections. The trial will compare two levels of immunoglobulin (antibody) su…

This study tests whether adding the drug selinexor to standard bispecific antibody therapy can help people with relapsed or refractory multiple myeloma achieve deeper remission. About 27 adults who have already tried at least 4 prior treatments will take the combination for up to…

This study looks at whether adding early palliative care to usual treatment helps people with multiple myeloma or aggressive B-cell lymphoma feel better. About 144 patients and their caregivers will either get early palliative care plus standard care or standard care alone. Resea…